Pharmacology Clinical studies have found that, on the basis of endometrial changes, E2-EN/DHPA appears, at the doses used, to be an estrogen-dominant combination. Pharmacokinetics By intramuscular injection, the elimination half-life of E2-EN has been found to be 5.6 to 7.5 days, while the half-life of<unk>  acetophenide and its metabolites has been found to be 24 days. Following a single injection, E2-EN and DHPA are detectable in the circulation for up to 30 to 60 days.
Estradiol enantate/algestone acetophenide
Estradiol benzoate butyrate/algestone acetophenide
Estradiol undecylate/norethisterone enanthate
Estradiol pivalate/progesterone
Elagolix/estradiol/norethindrone acetate
Estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone
Estradiol benzoate/estradiol phenylpropionate
Estradiol cypionate/testosterone cypionate